ALX ONCOLOGY HOLDINGS INC Net Income (Loss) Available to Common Stockholders, Basic
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$123.48 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-03-09
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$28.44M.
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$24.57M.
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$16.27M.
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was -$14.19M.
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for fiscal 2022 was -$123.48M.
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for fiscal 2021 was -$83.46M.
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for fiscal 2020 was -$50.94M.
- ALX ONCOLOGY HOLDINGS INC net income (loss) available to common stockholders, basic for fiscal 2019 was -$23.27M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$123.48M 10-K · filed 2023-03-09 | |||
| 2021-12-31 | -$28.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$53.00M derived: sum of 2 quarters · filed 2023-03-09 | -$69.28M derived: sum of 3 quarters · filed 2023-03-09 | -$83.46M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$24.57M 10-Q · filed 2021-11-12 | -$40.84M derived: sum of 2 quarters · filed 2021-11-12 | -$55.02M 10-Q · filed 2021-11-12 | -$73.80M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | -$16.27M 10-Q · filed 2021-08-12 | -$30.46M 10-Q · filed 2021-08-12 | -$49.23M derived: sum of 3 quarters · filed 2021-08-12 | -$59.99M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-03-31 | -$14.19M 10-Q · filed 2021-05-17 | -$32.96M derived: sum of 2 quarters · filed 2021-05-17 | -$43.72M derived: sum of 3 quarters · filed 2021-11-12 | -$57.69M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-12-31 | -$18.77M 10-K · filed 2021-03-18 | -$29.53M derived: sum of 2 quarters · filed 2021-11-12 | -$43.51M derived: sum of 3 quarters · filed 2021-11-12 | -$50.94M 10-K · filed 2023-03-09 |
| 2020-09-30 | -$10.76M 10-Q · filed 2021-11-12 | -$24.73M derived: sum of 2 quarters · filed 2021-11-12 | -$32.17M 10-Q · filed 2021-11-12 | -$41.00M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$13.97M 10-Q · filed 2021-08-12 | -$21.41M 10-Q · filed 2021-08-12 | -$30.24M derived: sum of 3 quarters · filed 2021-08-12 | -$34.36M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$7.44M 10-Q · filed 2021-05-17 | -$16.27M derived: sum of 2 quarters · filed 2021-05-17 | -$20.39M derived: sum of 3 quarters · filed 2021-05-17 | -$25.57M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$8.84M 10-K · filed 2021-03-18 | -$12.95M derived: sum of 2 quarters · filed 2021-03-18 | -$18.13M derived: sum of 3 quarters · filed 2021-03-18 | -$23.27M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$4.12M 10-K · filed 2021-03-18 | -$9.29M derived: sum of 2 quarters · filed 2021-03-18 | -$14.44M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$5.18M 10-K · filed 2021-03-18 | -$10.32M 10-Q · filed 2020-08-27 | ||
| 2019-03-31 | -$5.14M 10-K · filed 2021-03-18 | |||
| 2018-12-31 | -$17.40M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |